Kolexia
Vey Norbert Hématologie
Vey Norbert
Hématologie
Centre Paoli-Calmettes
Marseille, France
648 Activités
284 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Leucémies Leucémie aigüe myéloïde Leucémie myéloïde Syndromes myélodysplasiques Leucémie-lymphome lymphoblastique à précurseurs B et T Tumeurs hématologiques Maladie du greffon contre l'hôte Leucémie myélomonocytaire chronique Préleucémie

Collaborateurs

Voir plus
Recher Christian
Recher Christian
Hôpital Purpan, Toulouse, France
Fenaux Pierre
Fenaux Pierre
Hôpital Saint-Louis, Paris, France
Blaise Didier
Blaise Didier
Centre Paoli-Calmettes, Marseille, France
Pigneux Arnaud
Pigneux Arnaud
Hôpital Haut-lévêque, Pessac, France

Industries

Voir plus
Novartis
19 collaboration(s)
Dernière en 2023
Amgen
17 collaboration(s)
Dernière en 2022
Celgene
9 collaboration(s)
Dernière en 2021
Servier
6 collaboration(s)
Dernière en 2022

Dernières activités

Voir plus
Long-term survival of AML treated with intensive chemotherapy with extensive molecular data available.
Leukemia & lymphoma   08 février 2024
A Single Center Real World Experience of Allogeneic HSCT of Patients with MDS/CMML in Aged Population
Abstracts from the 2024 Tandem Meetings of ASTCT and CIBMTR, February 21-24, 2024, San Antonio, Texas, USA   01 février 2024
VOYAGE: A Phase 1/2, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 DART® Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk Myelodysplastic Syndrome (MDS)
Essai Clinique (MacroGenics)   24 janvier 2024
Venetoclax and Cobimetinib in Relapsed/Refractory AML: A Phase 1b Trial.
Clinical lymphoma, myeloma & leukemia   18 janvier 2024
Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA: A Randomized Phase I/ II Multicenter Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA
Essai Clinique (Celgene)   02 janvier 2024
AVENHIR: Phase II Study With Safety run-in of Azacitidine (AZA) Combined With Venetoclax (VEN) in Patients With Higher-risk Chronic Myelomonocytic Leukemia (CMML)
Essai Clinique (Abbvie)   02 janvier 2024
EVICTION: A First-in-human, Two-part Clinical Study to Assess the Safety, Tolerability and Activity of IV Doses of ICT01 as Monotherapy and in Combination With a Checkpoint Inhibitor, in Patients With Advanced-stage, Relapsed/Refractory Cancer
Essai Clinique (ImCheck Therapeutics)   28 décembre 2023
Azacitidine-venetoclax versus azacitidine salvage treatment for primary induction failure or first relapsed acute myeloid leukaemia patients.
European journal of haematology   29 novembre 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.
American journal of hematology   22 novembre 2023
Advances in the Treatment of Myelodysplastic Syndromes - Medscape Education
Medscape   16 novembre 2023